Neil Sengupta to Remission Induction
This is a "connection" page, showing publications Neil Sengupta has written about Remission Induction.
Connection Strength
0.196
-
Higher vedolizumab serum levels do not increase the risk of adverse events in patients with inflammatory bowel disease. Scand J Gastroenterol. 2020 Jul; 55(7):800-805.
Score: 0.155
-
Comparative Efficacy and Rapidity of Action for Infliximab vs Ustekinumab in Biologic Naïve Crohn's Disease. Clin Gastroenterol Hepatol. 2022 07; 20(7):1579-1587.e2.
Score: 0.041